Integrilin

Integrilin is a brand name of eptifibatide, approved by the FDA in the following formulation(s):

INTEGRILIN (eptifibatide - injectable; injection)

• 
  Manufacturer: SCHERING
  
  Approval date: May 18, 1998
  
  Strength(s): 2MG/ML ^[RLD], 75MG/100ML ^[RLD]

Has a generic version of Integrilin been approved?

No. There is currently no therapeutically equivalent version of Integrilin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Integrilin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Platelet aggregation inhibitors
  Patent 5,686,570
  Issued: November 11, 1997
  Inventor(s): Scarborough; Robert M. & Wolf; David Lawrence & Charo; Israel F.
  Assignee(s): COR Therapeutics, Inc.
  An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formula EQU R.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO-- wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.5 is independently H or alkyl(1-6C); and wherein one or two (CH.sub.2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
  
  Patent expiration dates:
  
  
  • November 11, 2014
    
  
  



• 
  Stable polypeptide composition
  Patent 5,747,447
  Issued: May 5, 1998
  Inventor(s): Swift; Robert L. & Du Mee; Charles P. & Randolph; Anne
  Assignee(s): COR Therapeutics
  A (injectable biologically active) polypeptide is stabilized by dissolving said polypeptide forming a liquid solution in citrate buffer of about pH 5.0-5.5.
  
  Patent expiration dates:
  
  
  • May 5, 2015
    
  
  



• 
  Platelet aggregation inhibitors
  Patent 5,756,451
  Issued: May 26, 1998
  Inventor(s): Scarborough; Robert M. & Wolf; David Lawrence & Charo; Israel F.
  Assignee(s): COR Therapeutics, Inc.
  This invention relates to a group of peptides which are, or are related to, platelet aggregation inhibitors isolated and purified from various snake venoms. The instant platelet aggregation inhibitors inhibit (a) binding of Fg or vWF to GPIIb-IIIa more than (b) binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor. The peptides are useful as therapeutic agents for the treatment of, and prevention of, platelet-associated ischemic disorders.
  
  Patent expiration dates:
  
  
  • November 11, 2014
    
  
  



• 
  Platelet aggregation inhibitors
  Patent 5,807,825
  Issued: September 15, 1998
  Inventor(s): Scarborough; Robert M. & Wolf; David Lawrence & Charo; Israel F.
  Assignee(s): COR Therapeutics, Inc.
  An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formula EQU R.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO-- wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.5 is independently H or alkyl(1-6C); and wherein one or two (CH.sub.2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
  
  Patent expiration dates:
  
  
  • September 15, 2015
    
    ✓ 
    Patent use: PLATELET AGGREGATION INHIBITORS
  
  



• 
  Platelet aggregation inhibitors
  Patent 5,968,902
  Issued: October 19, 1999
  Inventor(s): Scarborough; Robert M. & Wolf; David Lawrence & Charo; Israel F.
  Assignee(s): COR Therapeutics, Inc.
  The isolated and purified PAI from several active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula EQU R.sup.1.sub.2 N(CH .sub.2).sub.4 CHNHCO-- wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4 .sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.5 is independently H or alkyl(1-6C); and wherein one or two (CH.sub.2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
  
  Patent expiration dates:
  
  
  • June 2, 2015
    
    ✓ 
    Patent use: TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
  
  

See also...

• Integrilin Consumer Information (Drugs.com)
• Integrilin Consumer Information (Wolters Kluwer)
• Integrilin Consumer Information (Cerner Multum)
• Integrilin Advanced Consumer Information (Micromedex)
• Integrilin AHFS DI Monographs (ASHP)
• Eptifibatide Consumer Information (Wolters Kluwer)
• Eptifibatide Consumer Information (Cerner Multum)
• Eptifibatide Intravenous Advanced Consumer Information (Micromedex)
• Eptifibatide AHFS DI Monographs (ASHP)